According to Grifols's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 9.16465. At the end of 2020 the company had a P/E ratio of 17.6.
Year | P/E ratio | Change |
---|---|---|
2020 | 17.6 | -23.07% |
2019 | 22.9 | 27.44% |
2018 | 17.9 | -12.49% |
2017 | 20.5 | 12.69% |
2016 | 18.2 | -4.33% |
2015 | 19.0 | -0.2% |
2014 | 19.1 | -28.67% |
2013 | 26.7 | 0.53% |
2012 | 26.6 | -34.07% |
2011 | 40.3 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 10.4 | 13.45% | ๐บ๐ธ USA |
Amgen AMGN | 19.1 | 107.87% | ๐บ๐ธ USA |
Baxter BAX | 7.85 | -14.32% | ๐บ๐ธ USA |
Kimberly-Clark KMB | 26.0 | 183.28% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.